CTGL pivots to UAV/defense amid zero cash, NIS12.5m grant and heavy dilution risk

CITRINE GLOBAL, CORP (PINK: CTGL) - snapshot of what's happening inside

* Quick summary: the company remains pre-revenue, operating largely through its Israeli subsidiaries, is pivoting toward defense/UAV activity (name changes noted) and is funding operations via convertible debt, related‑party support and government grants. The business is still in a development stage and carries material liquidity, dilution and related‑party risks.

Key facts & numbers (as reported; U.S. dollars in thousands unless noted)

* Shares outstanding: 1,044,074,409 (Sept 30, 2024); 1,234,185,009 as of Sept 3, 2025.
* Cash and cash equivalents: $0 at Sept 30, 2024 (was $7 at Dec 31, 2023).
* Total assets: $1,591 (Sept 30, 2024) vs $2,486 (Dec 31, 2023).
* Total liabilities: $5,665 (Sept 30, 2024).
* Stockholders' deficit: $(4,074).
* Accumulated deficit: $(31,389).
* Working capital deficiency: $3,187 (reported).
* Convertible notes - related parties (non-current liability): $2,363.
* Investments (measurement alternative): $1,263.
* Net loss - nine months ended Sept 30, 2024: $(1,882). Three months ended Sept 30, 2024: $(380).
* Operating loss - nine months: $(930); three months: $(263).
* Financing (income)/expenses, net - nine months: $(952) (large charge driven by IBOT/MyPlant option and related adjustments); three months: $(117).
* No revenue reported to Sept 30, 2024 (company remains pre‑revenue).
* Stock options outstanding: 121,351,132; exercisable 88,878,145; company stock price $0.0115 at Sept 30, 2024. Share‑based compensation nine months: $235; unrecognized cost $97 (expected ~1 year).
* Material subsequent items: government grant to Cannovation/SkyTech Orion - NIS 12.5m (~USD $3.4m) awarded Jan 12, 2025; conversions of convertible debt to equity (large share issuances); company and subsidiary name changes toward a SkyTech/defense focus; impairment recorded on an investment ~ $431 (June 2025).

Positive elements

* Government grant: NIS 12.5m (~$3.4m) awarded to the subsidiary for construction/reimbursements - significant non‑dilutive funding potential for the Yerucham project.
* Asset base: ownership/control of 11,687 sqm industrial land in Yerucham and a modular "Operational Innovation Centers" platform that management highlights as strategic.
* Debt-to-equity conversions: conversion of convertible loans into equity reduces near‑term cash servicing needs (but increases dilution).
* Operating cost control: quarter‑by‑quarter operating loss narrowed (Q3 2024 operating loss $263 vs Q3 2023 $524 - fewer non‑cash charges and lower R&D in the period).

Negative elements (income statement and financial health)

* Zero revenues - the company is pre‑revenue and cannot yet support operations from sales.
* Losses persist and increased on a nine‑month basis (net loss $1,882 vs $1,649 prior period) - driven largely by financing and fair‑value adjustments.
* Large financing charges: financing expenses (net) of $952 for nine months (main component: $747 related to IBOT/MyPlant option adjustments) materially worsened the bottom line.
* Cash crisis / working capital deficit: $0 cash and a working capital deficiency (~$3.2m) create consumption risk and reliance on external funding or related‑party support.
* Related‑party exposure: significant accrued compensation and payables to related parties ($2,326 accrued compensation; $204 accounts payable related parties) and convertible notes tied to related parties ($2,363) - concentration and governance risk.
* Heavy dilution risk: multiple large share issuances and debt conversions (hundreds of millions of shares issued), plus option pools - current and prospective holders face dilution.
* Market / listing risk: company was a delinquent filer in 2024, trading restricted and no active market - liquidity for shareholders is limited.
* Operational/geopolitical risk: headquarters and core operations in Israel exposed to war/instability that delayed product launches and fundraising.

What this means - concise takeaways

* Stage & strategy: CTGL is a development‑stage company transitioning strategy toward UAV/defense (multiple name changes) while maintaining botanical/wellness assets and the Yerucham site as a cornerstone asset.
* Liquidity & runway: short-term runway is fragile - cash is zero and operations depend on grant receipts, credit facility draws, related‑party financing and completed equity investments/conversions.
* Risk/return profile: high risk - no revenues, recurring losses, related‑party liabilities, and material dilution. Potential upside exists if government grant funds convert into project progress and the company successfully uplists or commercializes assets; but execution and funding must occur.
* Watch next catalysts: receipt and timing of grant reimbursements, completion of announced investments/conversions, construction progress at Yerucham (SkyTech Center), any uplisting activity, and cash balance updates.

Bottom line: CTGL is still a pre‑revenue, cash‑constrained development company with important strategic assets (Yerucham land and a new government grant) but also significant financing charges, related‑party exposure and dilution risk. Investors should monitor grant inflows, debt conversions, and proof of operational progress before assuming the company can translate assets into sustainable revenue.